Regeneron completes purchase of Sanofi's stake in Libtayo

Company provides anticipated impact to second quarter 2022 financial results due to recently completed business development transactions

Nykode Therapeutics enters multi-target license and collaboration agreement with Regeneron

The multi-target agreement covers five programmes focused on off-the-shelf vaccines for cancer and infectious disease

Biocon Biologics secures Canada market entry date for YESAFILI

This agreement paves the way for the introduction of YESAFILI into the Canadian market

Dupixent significantly reduced COPD exacerbations in second positive Phase 3 trial

Accelerating FDA submission and confirming potential to become first approved biologic for this serious disease

Dupixent is now approved in India for the treatment of adults with moderate-to-severe atopic dermatitis

Top 20 global biopharma companies report 3.4% fall in market cap in Q1 2023: GlobalData

Bayer reported the highest market capitalization growth of 23.1% during Q1 2023

Biogen appoints Christopher Viehbacher as President and CEO

Viehbacher brings extensive international experience in large pharmaceutical and entrepreneurial biotech companies

Sanofi Dupixent gets USFDA nod for atopic dermatitis

Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood

Shilpa Medicare receives NoC for biosimilar Aflibercept

Aflibercept is the second biosimilar product that has entered the clinical trial phase after biosimilar Adalimumab

Dupixent is a star in Sanofi’s immunology strategy

Dupixent peak sales ambition raised to more than €13 billion